# TROPION-Lung14 (NCT06350097)

> Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06350097
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: AstraZeneca
- Conditions: Non-small Cell Lung Cancer
- Interventions: Osimertinib; Datopotamab Deruxtecan
- Enrollment: 582
- Primary outcome: To demonstrate the superiority of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of Progression Free Survival (PFS) by BICR in all randomised participants.

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 8
- Podcasts: 7
- X threads: 5

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=tropion-lung14-nct06350097

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06350097", "email": "<work email>"}; the inbox owner confirms by the emailed link.